UC San Diego Receives Award from Advanced Research Projects Agency for Health (ARPA-H)
|
UC San Diego researchers, led by Moores Member Trey Ideker, PhD, are part of a $142 million ARPA-H initiative to advance personalized cancer treatments using AI through developing “digital tumors” and “drug recommender engines” to better match patients with therapies and predict disease progression, including cancer. Learn More>>
|
Why Clinical Trials Matter
|
Altman Clinical and Translational Research Institute Director and Moores Member David “Davey” Smith, MD, MAS described the process of developing and participating in clinical trials in a recent Q&A in UC San Diego Today. Learn More>>
|
Moores Intern Receives Kyoto Prize Scholarship
|
High school senior Adam Ramadan won this scholarship as part of the mentorship and opportunities he received from Moores Member Judith Varner, PhD, which piqued his interest in tumor immunology and translational oncology. Learn More>>
|
|
|
Call for Applications: National Lab Faculty Fellow
|
The UC San Diego Office of Research and Innovation is seeking a Faculty Fellow to help build collaborations with the National Laboratories through a renewable 2-year appointment, which involves (1) determining lab priorities, cores, and initiatives, (2) connecting lab partners to the broader campus, (3) developing a strategy to expand collaborations, and (4) representing UC San Diego lab-based working groups. Learn More and Apply>>
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
The Department of Defense (DOD), Congressionally Directed Medical Research Programs (CDMRP), Melanoma Research Program has released program announcements for the following funding opportunities. Learn More>>
|
Pre-proposals due June 30, 2025; invitation to submit full application required
|
- Idea Award
- Team Science Award
- Focused Program Award—Rare Melanomas
|
Letter of intent due September 10, 2025; invitation to submit full application not required
| - Melanoma Academy Scholar Award
- Melanoma Academy Leadership Award
- Survivorship Research Award
|
The DOD, CDMRP, Prostate Cancer Research Program has released program announcements for the following funding opportunities. Learn More>>
|
Letter of intent due August 8, 2025; invitation to submit full application not required
|
- Idea Development Award
- Clinical Consortium Award
|
|
|
SHARED RESOURCE SPOTLIGHT |
The Moores GCBSR provides consultation, data analysis, and training in advanced computational methods for cancer genomics. Serving over 40 Moores labs, GCBSR not only plays an essential role in research, grant submission, and education, but also continuously develops innovative computational methodologies. The data generation arm of GCBSR offers a variety of services: sequencing library preparation, high throughput sequencing on the Illumina NovaSeq X Plus or MiSeq i100, single-cell sequencing, spatial omics, genotyping and methylation arrays, and digital karyotyping. GCBSR possesses the most up-to-date instruments and state-of-the-art genomics technologies to provide users with the highest quality data. Contact GCBSR for a free consultation on the support available for your research>>
|
|
|
MOORES CANCER CENTER AT ASCO |
At the ASCO Annual Meeting 2025, taking place from May 30 — June 3 in Chicago, IL, our physician-scientists will present key findings on machine learning's role in trial design, GIST treatment breakthroughs, renal cell therapies and more.
|
Science in Session: Jyoti Mayadev, MD
|
Jyoti Mayadev, MD, and her research team are working to identify prognostic biomarkers in patients with locally advanced cervical cancer. Identifying these biomarkers could help advance standards of care for cervical cancer, and assist physicians in determining the best courses of care for their patients.
|
|
|
| Effect of phosphorylation barcodes on arrestin binding to a chemokine receptor
|
Tracy M. Handel, PhD (Solid Tumor Therapeutics)
|
|
|
| Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification
|
Elena Martinez, PhD (Cancer Control)
|
|
|
| APOBEC affects tumor evolution and age at onset of lung cancer in smokers
|
Erik N. Bergstrom, PhD (Structural and Functional Genomics [SFG]) and Ludmil B. Alexandrov, PhD (SFG)
|
|
|
CLINICAL TRIALS OFFICE (CTO)
|
IAM1363-01: A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations
PI: Kay Tsuen Yeung, MD, PhD
NCT ID: NCT06253871
MK-6482-029: A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK029)
PI: Jessica Sullivan, DO
NCT ID: NCT06428396
BNT327-06: A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in Firstline Non-small Cell Lung Cancer
PI: Lyudmila Bazhenova, MD
NCT ID: NCT06712316
|
|
|
|
